Finanzen von Chromadex Corp (CDXC)CDXCChromadex Corp

Chromadex Corp (CDXC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Consumer Products Segments, accounting for 70.8% of total sales, equivalent to $18.12M. Other significant revenue streams include Ingredients Segments and Analytical Reference Standards and Service segment. Understanding this composition is critical for investors evaluating how CDXC navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Chromadex Corp maintains a gross margin of 63.49%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 6.26%, while the net margin is 7.34%. These profitability ratios, combined with a Return on Equity (ROE) of 4.82%, provide a clear picture of how effectively CDXC converts its operational activities into shareholder value.

In the context of the broader market, CDXC competes directly with industry leaders such as USNA and ABVX. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, CDXC's gross margin of 63.49% stands against USNA's 78.35% and ABVX's N/A. Such benchmarking helps identify whether Chromadex Corp is trading at a premium or discount relative to its financial performance.